Comparison Overview

Vera Therapeutics, Inc.

VS

CSL

Vera Therapeutics, Inc.

2000 Sierra Point Pkwy, 1200, Brisbane, California, US, 94005
Last Update: 2026-03-27
View Profile
Between 750 and 799
http://www.veratx.com

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases to improve patients’ lives. Fraud alert for potential candidates for positions at Vera: your personal information and online safety are a top priority for us. At Vera Therapeutics, recruiters will only direct candidates to apply through our official career page at https://veratx.com/careers/. We will never request payments, ask for financial account information or sensitive information such as social security numbers. If you are unsure if a message is from Vera Therapeutics, please email [email protected].

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 175
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

CSL

655 Elizabeth St, Melbourne, 3000, AU
Last Update: 2026-04-02
Between 800 and 849
https://www.csl.com/

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 23,312
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/veratx.jpeg
Vera Therapeutics, Inc.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/csl.jpeg
CSL
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Vera Therapeutics, Inc.
100%
Compliance Rate
0/4 Standards Verified
CSL
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Vera Therapeutics, Inc. in 2026.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for CSL in 2026.

Incident History — Vera Therapeutics, Inc. (X = Date, Y = Severity)

Vera Therapeutics, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — CSL (X = Date, Y = Severity)

CSL cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/veratx.jpeg
Vera Therapeutics, Inc.
Incidents

No Incident

https://images.rankiteo.com/companyimages/csl.jpeg
CSL
Incidents

No Incident

FAQ

CSL company demonstrates a stronger AI Cybersecurity Score compared to Vera Therapeutics, Inc. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, CSL company has disclosed a higher number of cyber incidents compared to Vera Therapeutics, Inc. company.

In the current year, CSL company and Vera Therapeutics, Inc. company have not reported any cyber incidents.

Neither CSL company nor Vera Therapeutics, Inc. company has reported experiencing a ransomware attack publicly.

Neither CSL company nor Vera Therapeutics, Inc. company has reported experiencing a data breach publicly.

Neither CSL company nor Vera Therapeutics, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Vera Therapeutics, Inc. company nor CSL company has reported experiencing or disclosing vulnerabilities publicly.

Neither Vera Therapeutics, Inc. nor CSL holds any compliance certifications.

Neither company holds any compliance certifications.

CSL company has more subsidiaries worldwide compared to Vera Therapeutics, Inc. company.

CSL company employs more people globally than Vera Therapeutics, Inc. company, reflecting its scale as a Biotechnology Research.

Neither Vera Therapeutics, Inc. nor CSL holds SOC 2 Type 1 certification.

Neither Vera Therapeutics, Inc. nor CSL holds SOC 2 Type 2 certification.

Neither Vera Therapeutics, Inc. nor CSL holds ISO 27001 certification.

Neither Vera Therapeutics, Inc. nor CSL holds PCI DSS certification.

Neither Vera Therapeutics, Inc. nor CSL holds HIPAA certification.

Neither Vera Therapeutics, Inc. nor CSL holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Hirschmann EagleSDV version 05.4.01 prior to 05.4.02 contains a denial-of-service vulnerability that causes the device to crash during session establishment when using TLS 1.0 or TLS 1.1. Attackers can trigger a crash by initiating TLS connections with these protocol versions to disrupt service availability.

Published
Date
2026-04-02
Updated
Date
2026-04-02
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

The stored API keys in temporary browser client is not marked as protected allowing for JavScript console or other errors to allow for extraction of the encryption credentials.

Published
Date
2026-04-02
Updated
Date
2026-04-02
References
Description

XSS vulnerability in cveInterface.js allows for inject HTML to be passed to display, as cveInterface trusts input from CVE API services

Published
Date
2026-04-02
Updated
Date
2026-04-02
References
Description

Multiple reflected cross-site scripting (XSS) vulnerabilities in the login.php endpoint of Interzen Consulting S.r.l ZenShare Suite v17.0 allows attackers to execute arbitrary Javascript in the context of the user's browser via a crafted URL injected into the codice_azienda and red_url parameters.

Published
Date
2026-04-02
Updated
Date
2026-04-02
References
Description

A reflected cross-site scripting (XSS) vulnerability in the login_newpwd.php endpoint of Interzen Consulting S.r.l ZenShare Suite v17.0 allows attackers to execute arbitrary Javascript in the context of the user's browser via a crafted URL injected into the codice_azienda parameter.

Published
Date
2026-04-02
Updated
Date
2026-04-02
References